IntegraGen enters liquidation after court approves sale to ABL Diagnostics

• Commercial court in Évry ordered IntegraGen SA into judicial liquidation on Oct. 9, 2026.
• Court-approved sale transfers its genomics and bioinformatics services business to ABL Diagnostics, effective Oct. 9.
• Deal price set at EUR 100,000, allocated to creditor repayments in the liquidation process.
• Transaction includes the transfer of 16 employees.
• Shares remain outstanding with no buyout; investors face potential partial or total loss as delisting is expected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IntegraGen SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261012076105) on October 12, 2026, and is solely responsible for the information contained therein.